Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    C Peptide

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 105,340Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Imcyse Reports +ve Immune Response from Phase 2 IMPACT Type 1 Diabetes Study
    Imcyse Reports +ve Immune Response from Phase 2 IMPACT Type 1 Diabetes Study

    13 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/13/2366270/0/en/Imcyse-Reports-Positive-Immune-Response-from-Interim-Analysis-of-Phase-2-IMPACT-Type-1-Diabetes-Study.html

    GLOBENEWSWIRE
    13 Jan 2022
    Share Share
    Peptide-lipid nanoconstructs act site-specifically towards glioblastoma growth
    Peptide-lipid nanoconstructs act site-specifically towards glioblastoma growth

    27 Aug 2020

    // PHARMAEXCIPIENTS

    https://www.pharmaexcipients.com/nanotechnology/peptide-lipid-nanoconstructs/

    PHARMAEXCIPIENTS
    27 Aug 2020
    Share Share
    Caladrius Biosciences Reports Top-Line Data for Ph 2a: CLBS03 for T1D
    Caladrius Biosciences Reports Top-Line Data for Ph 2a: CLBS03 for T1D

    13 Feb 2019

    // GLOBENEWSWIRE

    https://globenewswire.com/news-release/2019/02/13/1725052/0/en/Caladrius-Biosciences-Reports-Top-Line-Data-for-the-Phase-2a-Sanford-Project-T-Rex-Trial-of-CLBS03-for-Recent-Onset-Type-1-Diabetes.html

    GLOBENEWSWIRE
    13 Feb 2019
    Share Share